Redd&Whyte Appoints HighRes Biosolutions as New US Distributor
News Feb 28, 2013
Redd&Whyte, an expert supplier of liquid handling automation for drug discovery and life science research applications, today announced it has appointed HighRes Biosolutions, a leading developer of flexible laboratory automation systems, as US distributor for its Preddator low-volume microplate dispensers. The appointment will provide US researchers with rapid access to, and support of, unique technology for achieving consistent results and reducing assay costs, by dispensing low-volumes of difficult reagents into microplates.
Under the terms of the agreement, HighRes Biosolutions will market Redd&Whyte’s Preddator range in North America. The versatile Preddator, which can dispense viscous liquids including gels, cell suspensions and DMSO in any microplate format from 96-3456 wells, will be integrated into HighRes’ patented MicroDock technology. This will allow scientists to easily add and remove the Preddator from HighRes’ automated assay preparation and screening systems.
Redd&Whyte chose HighRes to market its equipment in North America because the firm is respected for its modular design of versatile laboratory automation and specialist knowledge of integrating state-of-the-art liquid handlers into their systems. HighRes also has a large network of life science specialists across the USA, who will provide further information on integrated solutions that include the Preddator system.
Roger Poole, Managing Director of Redd&Whyte commented: "Recently, we have had great success in the North American market with our Preddator system and are delighted to have HighRes Biosolutions as our new distribution partner to support this growth.”
Poole added: “HighRes is a first-rate company, with an excellent reputation for its versatile approach to integrating only the best low-volume liquid handlers into their systems. Our unique, flexible low-volume microplate dispensing technology will perfectly complement the products HighRes provides so we’re excited to have them offering Preddator as part of their portfolio.”
New Drug to Treat Herpes Simplex Virus Infection?News
Researchers have now identified a small drug molecule that can clear the HSV-1 infection in the cells of the cornea -- the clear outer layer of the eyeball -- and works completely differently than the currently-available drugs, making it a promising potential option for patients who have developed resistance.READ MORE
Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate GrowthNews
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.READ MORE
Gaining a Deeper Understanding of Protein Kinases Involved in CancerNews
Vaccinia-related protein kinases VRK1 and VRK2, which are involved in cell proliferation, are considered potential targets for treatment of prostate, ovarian, colorectal and other kinds of cancer. To obtain a deeper understanding of the role of these enzymes in human cells, in the contexts of both wellness and disease, researchers are working on the development of small synthetic molecules capable of modulating their activity in study models.READ MORE